Article

From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer

Author(s):

Debu Tripathy

Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of man.
Image of thumbnail.
Patients can prepare personal overviews to help care teams connect with them as individuals, explained Michelle Kirschner in an interview with CURE.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Expanding on a New Way to Manage Polycythemia Vera Without Iron Deficiency
Image of woman.
Image of two people.
Related Content
I feel unprepared and overwhelmed after my breast cancer diagnosis, facing treatment like a race, hoping for the strength to reach the finish: © stock.adobe.com
June 15th 2025

Running a Race I Never Chose: Life During Cancer

Avis Yarbrough
I feel unprepared and overwhelmed after my breast cancer diagnosis, facing treatment like a race, hoping for the strength to reach the finish.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Image of hands.
June 14th 2025

From Patient to Researcher: It’s Not All About the Cure

Jessica López
I’m working to make cancer treatments less painful by developing donor-derived CAR therapies, so others don’t have to suffer the way I did.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Image of debbie.
June 13th 2025

Survivorship, the Hardest Part After Cancer?

Debbie Legault
Survivorship after cancer can be harder than treatment. My daughter faces lasting side effects, fear, and uncertainty while building a life she hopes to live fully.
Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer: © stock.adobe.com.
June 13th 2025

Similar Outcomes Yielded Between Surgery and Radiation in Low-Risk Prostate Cancer

Spencer Feldman
Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining treatments, experts said.